New Immunotherapy-Chemo combo aims to tackle rare sarcoma
NCT ID NCT07243626
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding envafolimab (an immunotherapy) to standard chemotherapy (doxorubicin and ifosfamide) can improve outcomes for people with advanced soft tissue sarcoma who haven't had prior treatment. About 25 adults will receive the combination every 3 weeks. The study will measure how long the cancer stays under control and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
envafolimab (a PD-L1 inhibitor) combined with doxorubicin and ifosfamide (chemotherapy)
What this could lead to
If successful, this could offer a more effective first-line treatment option for advanced soft tissue sarcoma, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is a small, early-phase trial (25 participants) with no control group, so results may not be conclusive. The combination may cause significant side effects, and not all sarcoma subtypes may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
RECRUITINGHanzhong, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••